Octave
Octave Bioscience is a precision neurology company whose flagship MSDA Test uses an 18-biomarker serum assay and proprietary ML algorithm to generate a 1–10 multiple sclerosis disease activity score from a single blood draw, sold to U.S. neurologists via a sales-led motion and distributed through Quest Diagnostics' 7,000+ phlebotomy sites.
- Company typePrivate
- Founded2014
- HeadquartersMenlo Park, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Octave does
Octave Bioscience, Inc. is a privately held precision neurology company founded in 2014 and headquartered in Menlo Park, California. Its flagship commercial product is the Octave Multiple Sclerosis Disease Activity (MSDA) Test, the first multi-protein, blood-based biomarker assay specifically designed for multiple sclerosis. The test measures 18 serum protein biomarkers across four biological pathways (Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity) and applies a proprietary machine-learning algorithm — trained on thousands of prior MS patient profiles — together with patient demographics and clinical context to generate a single Disease Activity Score from 1–10. All processing occurs in a CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory, with HITRUST, ISO/IEC 27001:2022, and ISO/IEC 42001:2023 certifications governing information security and AI management.
The company generates revenue primarily through per-test unit pricing reimbursed by insurance, with in-network coverage spanning 75M+ lives and payer contracts covering 84M+ member lives. Distribution is sales-led but materially augmented by a December 2025 strategic collaboration with Quest Diagnostics, which provides blood-draw access across approximately 7,000 patient service centers nationwide, complemented by partnerships with Any Lab Test Now and ARCpoint Labs. The primary customer is the ordering neurologist or MS specialist, who uses the MSDA Test to inform disease-modifying therapy (DMT) initiation, switching, monitoring, and de-escalation decisions; patients act as end users rather than direct payers in most cases. Beyond MS, Octave is extending its biomarker platform into an in-development MS Disease Progression (MSDP) Test (funded by the Valhalla Foundation) and an in-development Parkinson's disease multi-protein biomarker panel (funded by a $10M Michael J. Fox Foundation grant), with Alzheimer's identified as a future expansion target.
Octave has raised approximately $94M+ across disclosed funding events, including a $35M Series C and $15.5M debt facility in September 2025, and is backed by Kleiner Perkins, Northpond Ventures, Section 32, Casdin Capital, Deerfield, Echo Health Ventures, Merck Global Health Innovation Fund, Novartis (drX), Hikma, Intermountain, and the BlueCross BlueShield Fund (Sandbox Industries). Strategic pharmaceutical relationships include a Merck GHI investment and a multi-asset collaboration with TG Therapeutics generating real-world evidence for ublituximab (BRIUMVI). As of April 2026, the company reported 29,000+ scores delivered to 500+ prescribers across 20,000+ patients, with all 50 U.S. states served and a projected 300% annual growth rate for 2026.
Octave firmographics
Firmographics- Name
- Octave
- Legal name
- Octave Bioscience, Inc.
- Website
- https://octavebio.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Octave Bioscience is a precision neurology company whose flagship MSDA Test uses an 18-biomarker serum assay and proprietary ML algorithm to generate a 1–10 multiple sclerosis disease activity score from a single blood draw, sold to U.S. neurologists via a sales-led motion and distributed through Quest Diagnostics' 7,000+ phlebotomy sites.
- Ownership category
- akta.pro rank
Octave industry classification
Industry- Product category
- Clinical Diagnostic Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)
- akta.pro secondary industries
- Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF) (HLACAFAA), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where Octave is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Octave business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Diagnostic test sales (per-test unit pricing): Revenue is generated per MSDA Test ordered and processed. The test is paid primarily through reimbursement from insurance (Octave accepts all insurances) with patients paying any remaining out-of-pocket balance. Flexible payment plans and the Octave Cares financial assistance program are offered for eligible patients. Reimbursement is in-network for 75M+ lives (as of 2025) and payer contracts cover 84M+ member lives.
- Quest Diagnostics channel volume: After December 2025 partnership with Quest Diagnostics, a portion of revenue scales with test volume referred through Quest's ~7,000 patient service centers nationwide, expanding patient access and billable test volume.
- Non-dilutive grant funding (R&D): Non-revenue but material capital source: $10M grant from The Michael J. Fox Foundation for Parkinson's biomarker development and Valhalla Foundation grant funding for the MSDP (MS disease progression) Test development. These fund R&D pipeline expansion rather than commercial sales.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Insurance-billed diagnostic test with patient financial assistance |
| Other | Pay-as-you-go | Patient self-pay / out-of-pocket option |
Go-to-market motion4 records
Distribution channels1 record
Marketing channels9 records
Octave product offering
Product offeringCore offering
Octave develops, validates, and delivers blood-based multi-protein biomarker diagnostic tests for neurodegenerative diseases. Its flagship commercially available product, the Octave MSDA Test, is a serum assay that measures 18 protein biomarkers across 4 biological pathways and uses a machine-learning algorithm to generate a personalized 1-10 Disease Activity Score for multiple sclerosis. The same platform underpins in-development products for MS disease progression (MSDP Test) and Parkinson's disease, with all samples processed in Octave's CLIA-certified, CAP-accredited, NY State CLEP-approved clinical laboratory.
Product overview
Octave Bioscience is a precision neurology company built around a single unified biomarker-testing platform that converts blood-based multi-protein measurements into quantitative disease activity and (eventually) disease progression scores. Its commercially available flagship is the Octave MSDA Test for multiple sclerosis, which underlies and is the first productized output of the underlying Octave Care Management Platform for neurodegenerative diseases. The same platform architecture is being extended to additional pipeline products: the in-development MSDP Test for MS disease progression (funded by the Valhalla Foundation) and the in-development Parkinson's Disease Biomarker Panel (funded by The Michael J. Fox Foundation), with Alzheimer's identified as a future extension. All tests are processed in a CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory, with samples collected via a partner phlebotomy network including Quest Diagnostics (7,000+ sites) and Any Lab Test Now.
Differentiator
Problem solved
Functional benefit
Brands
- MSDA Test: Octave's flagship multi-protein, blood-based biomarker test for multiple sclerosis disease activity, generating a 1-10 Disease Activity Score from 18 serum protein biomarkers across four biological pathways.
- MSDP Test
Products and services
- Octave MSDA Test (Multiple Sclerosis Disease Activity Test) Flagship commercially available multi-protein, blood-based biomarker assay for multiple sclerosis that measures 18 serum protein biomarkers across 4 biological pathways (Immunomodulation, Neuroinflammation, Myelin Biology, Neuroaxonal Integrity) and uses a machine-learning algorithm to generate a personalized Disease Activity Score from 1-10 for ordering U.S. neurologists and MS specialists, supporting DMT initiation, switching, monitoring, and treatment optimization. Processed in Octave's CLIA-certified, CAP-accredited, NY State CLEP-approved laboratory.
- MSDP Test (Multiple Sclerosis Disease Progression Test) In-development blood-based biomarker test designed to provide an objective measure of multiple sclerosis disease progression across multiple MS types, intended to inform earlier treatment decisions. Development is supported by a grant from the Valhalla Foundation.
- Parkinson's Disease Biomarker Panel In-development world's-first multi-protein, blood-based assay for Parkinson's disease, funded by a $10 million grant from The Michael J. Fox Foundation, with the goal of improving disease assessment, research, and management of neurodegenerative disease.
Quantifiable outcome
- 1 in 5 documented clinical-decision changes after MSDA testing
- +7 more outcomes
Companies that use Octave
Customer profileSegments4 records
Ideal customer profiles2 records
Octave technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature5 records
Octave partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship, minor and strategic.
- Quest DiagnosticsflagshipOctave Bioscience formed a strategic collaboration with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest's nationwide network of approximately 7,000 patient access sites in the United States. The partnership aims to improve diagnosis and management of MS by providing a reliable blood test for disease activity, and establishes a pathway for future tests from Octave's neurology portfolio.
- CodewordminorCodeword, a communications and marketing agency, added Octave to its client roster alongside Demandbase and Root Insurance. The engagement supports brand narrative, market leadership positioning, and strategic communication during product launches.
- Accelerated Cure Project for Multiple Sclerosis (ACP)strategicLong-standing partnership with the Accelerated Cure Project for Multiple Sclerosis. ACP's Chief Scientific Officer Stephanie Buxhoeveden highlights the collaboration as enabling demonstration of proteomic associations with clinically defined relapse in MS, which was crucial for developing the MSDA Test.
- TG TherapeuticsstrategicTG Therapeutics presented clinical data generated with the Octave MSDA Test for its FDA-approved MS drug BRIUMVI (ublituximab-xiiy) at ACTRIMS Forum 2026, including real-world infusion experience from the ENABLE Phase 4 observational study. Octave also presented a poster on multi-protein biomarker test results from the ENHANCE study of ublituximab at ACTRIMS 2026.
- Any Lab Test NowstrategicAny Lab Test Now is part of Octave's nationwide partner lab draw network; the Octave website provides a searchable state-by-state directory of Any Lab Test Now and ARCpoint Labs locations for blood draws.
Scale indicators15 records
Recent moves6 records
Expansion highlights7 records
Octave competitors and assessment
Company assessmentDirect peers
- Quanterix Corporation: Operates the Simoa single-molecule-array platform for ultra-sensitive blood-based protein biomarker detection, the closest architectural analog to Octave's multi-analyte serum biomarker approach, with overlapping neuroscience and neurodegeneration applications.
- Meso Scale Diagnostics: Provides multiplexed electrochemiluminescence immunoassay platforms for simultaneous measurement of multiple protein biomarkers in serum, directly comparable to Octave's 18-biomarker panel and Disease Activity Score use case.
Broad incumbents
- Myriad Genetics: Established molecular-diagnostics company with a specialty-lab commercial model, payer-reimbursement infrastructure, and clinician-direct sales motion, comparable to Octave's go-to-market but with a genetic rather than proteomic focus.
- Natera: Specialty lab with proprietary molecular assays, in-network commercial-payer coverage, and a direct-to-clinician sales model, structurally analogous to Octave's commercial motion in a different indication area.
- Veracyte: Specialty diagnostics company that combines proprietary genomic assays with a clinical-utility evidence-generation strategy to drive payer coverage and clinician adoption, a comparable commercial playbook to Octave's MSDA Test.
- Adaptive Biotechnologies: Immune-profiling diagnostics company with a CLIA-certified lab, payer coverage, and pharma partnerships, sharing the specialty-lab + clinical-evidence + strategic-partner model with Octave.
- Roche Diagnostics: Global in-vitro diagnostics incumbent with broad neurology and immunology assay menus, including MS-related biomarkers; represents the large-pharma competitive backdrop against which Octave must position its specialty multi-analyte test.
- Abbott Diagnostics: Major diagnostics incumbent with neurology and immunology assay franchises and a global clinical-lab footprint, a relevant strategic-comparator and potential partner/acquirer for a specialty neurodegenerative-diagnostics player like Octave.
- Siemens Healthineers: Broad in-vitro diagnostics platform with established neurology and specialty-assay channels in US hospital and reference-lab networks, a relevant incumbent comparator for Octave's specialty-lab positioning.
- Foundation Medicine (Roche): Specialty molecular-diagnostics company now within Roche, demonstrating the specialty-lab-to-pharma-strategic-exit pathway that Octave's platform-extension and pharma-investor base could also pursue.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights8 records
Customer concentration
Octave social profiles
Digital presenceOctave compliance and trust
Trust signalCompliance8 records
Octave financial estimates
Financial estimateRevenue estimate
Valuation estimate
Octave leadership team
Management profileNumber of profiles
Profiles15 records
Octave funding detail
Funding detailFunding overview
Funding rounds9 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Octave M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Octave
What does Octave do?
Octave develops, validates, and delivers blood-based multi-protein biomarker diagnostic tests for neurodegenerative diseases. Its flagship commercially available product, the Octave MSDA Test, is a serum assay that measures 18 protein biomarkers across 4 biological pathways and uses a machine-learning algorithm to generate a personalized 1-10 Disease Activity Score for multiple sclerosis. The same platform underpins in-development products for MS disease progression (MSDP Test) and Parkinson's disease, with all samples processed in Octave's CLIA-certified, CAP-accredited, NY State CLEP-approved clinical laboratory.
Is Octave a public or private company?
Octave is a private company. It is classified as venture growth investor backed and is currently operating.
When was Octave founded?
Octave was founded in 2014. It employs 101 to 250 people.
Where is Octave based?
Octave is headquartered in Menlo Park, United States, in the North America region.
How does Octave make money?
Three revenue lines are on record. Diagnostic test sales (per-test unit pricing) is the primary driver. The others are quest Diagnostics channel volume and non-dilutive grant funding (R&D).
Who are Octave's main competitors?
Direct peers on record are Quanterix Corporation and Meso Scale Diagnostics. Broad incumbents are Myriad Genetics, Natera, Veracyte, Adaptive Biotechnologies, Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers and Foundation Medicine (Roche).
Does Octave have an API?
No public API is recorded for Octave.
What industry is Octave in?
Octave's product category is Clinical Diagnostic Services. Its primary akta.pro industry code is HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring), with a secondary code of HLACAFAA, Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF). Its NAICS code is 621511 and its SIC code is 2835.